A Systematic Review of Pharmacological Pain Management in Multiple Sclerosis
- 1.1k Downloads
Both chronic and acute pain have been cited as the most common symptoms amongst patients with multiple sclerosis (MS), with recent prevalence estimates as high as 83 %. The evidence for spasticity and trigeminal neuralgia pharmacological treatments in MS has been systematically reviewed, but no equivalent reviews have been published concerning MS pain unrelated to these two conditions.
Our objective was to systematically review pain management strategies for the reduction of non-spastic and non-trigeminal neuralgic pain in MS patients.
Experimental studies published after 1965 were chosen for review by searching electronic databases (e.g. PubMed, Cumulative Index to Nursing and Allied Health Literature, Science Citation Index Expanded, Conference Proceedings Citation Index-Science, and clinicaltrials.gov) and bibliographies/citations of previously published reviews.
Studies were included if all participants were adults clinically diagnosed with MS, study sample was not restricted to participants with spasticity or trigeminal neuralgia, and participant-reported pain was a primary or secondary outcome measured with a validated tool.
Study Appraisal and Synthesis Methods
Records were screened and methodological qualities of included studies were assessed independently by two reviewers under the supervision of another reviewer using the principles recommended in the Cochrane Handbook for Systematic Review of Interventions and the levels of evidence espoused by the American Academy of Neurology.
Fifteen studies met the inclusion and exclusion criteria for review; interventions included antidepressants, anticonvulsants, dextromethorphan/quinidine, cannabinoids, and opioids/opioid antagonists. The pooled effect size for anticonvulsants (4 studies, 78 participants) was −1.88 (95 % CI: −3.13 to −0.64). The pooled effect size for cannabinoids (3 studies, 565 participants) was 0.08 (95 % CI: −0.74 to 0.89). Overall, only four trials reported Class 1 evidence. For these trials, dizziness was the most commonly reported adverse event, followed by nausea and somnolence.
The relatively small number of trials in MS patients with chronic pain precludes specific recommendations for treatment strategies. The review did not reveal any studies of drug combinations.
More trials with rigorous design and reporting are needed to determine effective treatments for specific pain types presenting in people living with MS.
KeywordsMultiple Sclerosis Multiple Sclerosis Patient Naltrexone Pregabalin Duloxetine
Dr. Lapane serves as a consultant to Janssen. Dr. Oh, Dr. Jawahar and Mr. Yang have no conflicts of interest to report.
No funds were received to support this research.
- 2.Brichetto G, Messmer Uccelli M, Mancardi GL, Solaro C. Symptomatic medication use in multiple sclerosis. Mult Scler. 2003;9:458–60.Google Scholar
- 7.Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113–e88.Google Scholar
- 11.Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;(4):CD001332.Google Scholar
- 12.Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.Google Scholar
- 13.Schumacher M, Hussain R, Gago N, Oudinet JP, Mattern C, Ghoumari AM. Progesterone synthesis in the nervous system: implications for myelination and myelin repair. Frontiers Neurosci. 2012;6:10.Google Scholar
- 16.Poser C, Brinar VV. Diagnostic criteria for multiple sclerosis. Clin Neurol Neurosurg. 2001;103:1–11.Google Scholar
- 26.Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2011; No. Version 5.1.0 (updated March 2011).Google Scholar
- 37.Eli Lilly & Co. Duloxetine for multiple sclerosis pain [ClinicalTrials.gov identifier NCT00755807]. US National Institutes of Health, ClinicalTrials.gov. Available from URL: http://www.clinicaltrials.gov. Accessed 28 Aug 2013.
- 38.GW Pharmaceuticals Ltd. Sativex versus placebo when added to existing treatment for central neuropathic pain in MS [ClinicalTrials.gov identifier NCT00391079]. US National Institutes of Health, ClinicalTrials.gov. Available from URL: http://www.clinicaltrials.gov. Accessed 28 Aug 2013.
- 44.Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2009;9:59.Google Scholar
- 47.Hobson K. Lawmakers aren’t laughing about Avanir’s price for nuedexta. Wall Street J. 2011. Available from: http://blogs.wsj.com/health/2011/05/25/lawmakers-arent-laughing-about-avanirs-price-for-nuedexta/. Accessed 6 March 2013.
- 49.Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;(3):CD007938.Google Scholar
- 50.Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;(3):CD007076.Google Scholar
- 51.Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009;(4):CD007115.Google Scholar
- 52.Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006;(3):CD006146.Google Scholar
- 54.Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012;7:CD008943.Google Scholar